Healthcare Capital Corp. Announces Closing of Upsized $275,000,000 Initial Public Offering

Rhea-AI Summary

Healthcare Capital Corp. successfully completed its upsized initial public offering, raising $275 million by selling 27.5 million units at $10.00 per unit. The offering includes 3.5 million units issued due to underwriters’ over-allotment option. Trading for the units commenced on Nasdaq under the ticker symbol HCCCU. Each unit comprises one share of Class A common stock and one-half of a redeemable warrant, exercisable at $11.50. The company aims to target mergers in the healthcare sector, particularly in digital health and technology.

Positive

• Raised $275 million in IPO proceeds.
• Focus on mergers in the growing healthcare industry.

Negative

• Potential dilution due to the nature of the unit offerings.

Wilmington, DE, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (the “Company”) announced today that it closed its upsized initial public offering of 27,500,000 units at $10.00 per unit, including 3,500,000 units issued pursuant to an exercise by the underwriters of their over-allotment option, resulting in gross proceeds of $275,000,000.

The Company’s units are listed on the Nasdaq Capital Market (“Nasdaq”) and commenced trading under the ticker symbol “HCCCU” on January 14, 2021. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “HCCC” and “HCCCW,” respectively.

The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any industry, it currently intends to concentrate its search for a target business operating in the healthcare industry, with a focus on digital and telehealth, life sciences, innovative medical devices and healthcare technology. The Company is led by Dr. David Milch, Chairman of the Board; William Johns, Chief Executive Officer and Director; and Philip A. Baseil, Chief Financial Officer.

Cantor Fitzgerald & Co. acted as the sole book running manager for the offering.

Of the proceeds received from the consummation of the initial public offering and a simultaneous private placement of warrants, $275,000,000 (or $10.00 per unit sold in the public offering) was placed in the Company’s trust account. An audited balance sheet of the Company as of January 20, 2021 reflecting receipt of the proceeds upon consummation of the initial public offering and the private placement will be included as an exhibit to a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission (“SEC”).

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor New York, New York 10022; Email: prospectus@cantor.com.

Registration statements relating to these securities have been filed with the SEC and were declared effective on January 14, 2021.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s final prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

William Johns
Chief Executive Officer and Director
Healthcare Capital Corp.
bill@wjohns.com

FAQ

What are the details of the HCCCU IPO?

Healthcare Capital Corp. raised $275 million in its IPO by selling 27.5 million units at $10.00 each, including 3.5 million units from underwriters' over-allotment.

What is the purpose of the IPO proceeds for HCCCU?

The proceeds from the IPO will be used for mergers and acquisitions in the healthcare sector, targeting digital health and technology companies.

When did HCCCU start trading on Nasdaq?

HCCCU commenced trading on Nasdaq on January 14, 2021.

What do the HCCCW warrants entitle holders to do?

Each whole warrant (HCCCW) allows the holder to purchase one share of Class A common stock at a price of $11.50.